ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?

H Bruckmueller, I Cascorbi - Expert opinion on drug metabolism & …, 2021 - Taylor & Francis
Introduction Interindividual differences in drug response are a frequent clinical challenge
partly due to variation in pharmacokinetics. ATP-binding cassette (ABC) transporters are …

Pharmacogenetics of OPRM1

RC Crist, WH Berrettini - Pharmacology Biochemistry and Behavior, 2014 - Elsevier
Pharmacogenetic research has the potential to explain the variation in treatment efficacy
within patient populations. Understanding the interaction between genetic variation and …

Opioid-induced respiratory depression: ABCB1 transporter pharmacogenetics

S Sadhasivam, V Chidambaran, X Zhang… - The …, 2015 - nature.com
Opioid-related respiratory depression (RD) is a serious clinical problem as it causes multiple
deaths and anoxic brain injuries. Morphine is subject to efflux via P-glycoprotein transporter …

Impact of ABCB1 and CYP2B6 Genetic Polymorphisms on Methadone Metabolism, Dose and Treatment Response in Patients with Opioid Addiction: A Systematic …

BB Dennis, M Bawor, L Thabane, Z Sohani, Z Samaan - PloS one, 2014 - journals.plos.org
Background Genetic variability may influence methadone metabolism, dose requirements,
and risk of relapse. Objectives To determine whether the CYP2B6* 6 or ABCB1 (rs1045642) …

[HTML][HTML] Reviewing pharmacogenetics to advance precision medicine for opioids

L Magarbeh, I Gorbovskaya, B Le Foll, R Jhirad… - Biomedicine & …, 2021 - Elsevier
Background Adequate opioid prescribing is critical for therapeutic success of pain
management. Despite the widespread use of opioids, optimized opioid therapy remains …

Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review

DA Volpe, Y Xu, CG Sahajwalla, IR Younis… - Journal of …, 2018 - Elsevier
Methadone is utilized for the treatment of individuals with opiate dependence. Methadone
undergoes N-demethylation by multiple cytochrome P450 (CYP) enzymes including …

Endogenous opiates and behavior: 2013

RJ Bodnar - Peptides, 2014 - Elsevier
This paper is the thirty-sixth consecutive installment of the annual review of research
concerning the endogenous opioid system. It summarizes papers published during 2013 …

Characterization of the safety and pharmacokinetic profile of D-methadone, a novel N-methyl-D-aspartate receptor antagonist in healthy, opioid-naive subjects: results …

G Bernstein, K Davis, C Mills, L Wang… - Journal of Clinical …, 2019 - journals.lww.com
Methods We conducted 2 phase 1, double-blind, randomized, placebo-controlled, single-
and multiple-ascending-dose studies to investigate the safety and tolerability of oral d …

Pharmacogenetics of opioid use disorder treatment

RC Crist, TK Clarke, WH Berrettini - CNS drugs, 2018 - Springer
Opioid use disorder (OUD) is a significant health problem in the United States and many
other countries. A combination of issues, most notably increased prescription of opioid …

The effect of acute morphine on obstructive sleep apnoea: a randomised double-blind placebo-controlled crossover trial

L Rowsell, KKH Wong, BJ Yee, DJ Eckert, AA Somogyi… - Thorax, 2019 - thorax.bmj.com
Objective Anaesthesiology guidelines suggest that opioids worsen obstructive sleep apnoea
(OSA) despite no randomised controlled trial evidence. We therefore conducted a …